San Francisco—Intranasal ketamine is emerging as a clinical tool to address pain caused by chronic refractory migraine in patients who have failed to respond to at least five classes of preventive treatment.
In a new study, nearly half (49%) of participants using intranasal ketamine to treat chronic refractory migraine reported that the treatment was “very effective,” and an additional 40% reported that the treatment was “somewhat effective.” However, almost